The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Martynov M.U.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnology of the Federal Medical Biological Agency
Bogolepova A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency
Yasamanova A.N.
Pirogov Russian National Research Medical University
Endothelial dysfunction in COVID- 19 and cognitive impairment
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(6): 93‑99
Views: 10763
Downloaded: 613
To cite this article:
Martynov MU, Bogolepova AN, Yasamanova AN. Endothelial dysfunction in COVID- 19 and cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry.
2021;121(6):93‑99. (In Russ.)
https://doi.org/10.17116/jnevro202112106193
Endothelial dysfunction is an important mechanism underlying multiple organ and systems failure in COVID-19. The development of endothelial dysfunction in COVID-19 can disrupt organ perfusion and cause a procoagulant state, leading to both macro- and microvascular thrombotic events. Cognitive impairment is a common complication of COVID-19 that develop in acute and delayed periods and is not directly related to the severity of the underlying disease. Treatment of endothelial dysfunction in patients with COVID-19 should take into account the leading pathogenetic factors of its development and with the development of neurological, including cognitive, disorders should include neuroprotective drugs. One of these drugs is actovegin, which has been shown to be effective in improving endothelial function, microcirculation and cognition.
Keywords:
Authors:
Martynov M.U.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnology of the Federal Medical Biological Agency
Bogolepova A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency
Yasamanova A.N.
Pirogov Russian National Research Medical University
Received:
08.05.2021
Accepted:
19.05.2021
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.